A meningitis awareness website has one job: help someone recognise the signs fast enough to act. If the site fails accessibility, it fails that job, and it now fails the law.
Think about who opens ensemblecontrelameningite.be at 11pm. A parent watching a feverish child. A grandparent unsure whether a stiff neck is serious. A teacher scanning between classes. None of them are reading at leisure. All of them are scanning under stress, often on a phone, sometimes with a screen reader, sometimes with shaking hands. The design has to hold up under those conditions.
Promedia recently completed a WCAG audit of GSK's Belgian meningitis awareness platform, following the same methodology applied earlier this year to disease awareness sites for J&J and Amgen. What follows is what a serious WCAG audit on a pharma disease awareness website actually involves, and why 2026 is the year Medical Affairs and brand teams can no longer treat accessibility as a nice-to-have.
An audit worth paying for is not a browser plugin scan. Automated tools catch roughly 30 to 40 percent of accessibility barriers. The rest, the ones that actually stop a caregiver from finding the emergency signs of meningitis, only surface through manual testing with assistive technologies across real user workflows.
Promedia's methodology follows WCAG 2.1 Level AA, the standard the European Accessibility Act uses via the harmonised European norm EN 301 549. The audit scans pages and individual nodes, then layers manual testing on top. Findings are structured by page, severity, and remediation priority, so the output is not a 200-page PDF that sits on a shared drive. It is an actionable backlog that a design and development team can start closing on Monday morning.
On a disease awareness site, the workflows we test are the ones that matter under pressure:
Every WCAG success criterion counts, but a handful decide whether a health message lands. Text contrast against background is the first. A pale grey subheading on a white card looks elegant in Figma and disappears on a five-year-old Android outdoors. Font sizing and reflow on mobile come next, because the audience is overwhelmingly reading on phones, often with system text scaled up.
Logical heading hierarchy is what lets a screen reader user jump straight to "signs and symptoms" without listening to the entire homepage. Keyboard navigation and visible focus indicators matter for anyone with a motor impairment, a broken trackpad, or simply a preference for the tab key. Accessible forms, with programmatic labels and clear error messages, decide whether a worried parent can request more information or gives up halfway.
These map cleanly to the POUR principles that EN 301 549 uses to assess compliance: Perceivable, Operable, Understandable, Robust. A pharma awareness site that fails on Perceivable is not just excluding users. It is losing the seconds that matter most.
Roughly 101 million people over the age of 16 in Europe live with some form of disability, close to 25 percent of the population. That is the population an inaccessible awareness site fails to reach. But the argument is not only about permanent disability. It is about the situational impairments that describe almost everyone visiting a meningitis site: stress, low light, one hand on a child, poor connection, unfamiliar medical vocabulary.
The quality problem is real. A large JMIR study of 693 rare disease information websites found only 33 percent cited sources, only 30 percent adequately declared conflicts of interest, and zero percent offered content in simple language. Pharma awareness sites are not competing only with other disease pages. They compete with confusion, misinformation, and Reddit threads, while families are under time pressure.
An accessible, well-structured awareness site is therefore not a compliance chore. It is the difference between a caregiver acting in the first hour and acting in the third. In meningitis, that gap is measured in outcomes, not analytics.
A proper audit combines automated scanning with manual testing using assistive technologies. It reviews text contrast, font sizing and reflow, heading hierarchy, keyboard navigation, focus indicators, form labels and error handling, alt text on medical imagery, and screen reader behaviour across the site's real user journeys. Findings are prioritised by severity and mapped to remediation actions.
On a symptom-recognition site, inaccessible design costs time. A caregiver who cannot read low-contrast text, cannot scale fonts, or cannot navigate to emergency guidance quickly may delay action. For conditions like meningitis or sepsis, where outcomes depend on hours, an accessibility failure becomes a patient safety issue, not only a compliance one.
If you own a disease awareness or patient information site in the EU, the practical next step is a manual WCAG 2.1 AA audit against EN 301 549, followed by a prioritised remediation plan and a published accessibility statement. Automated scans alone will not hold up to a regulator's inspection or a complainant's lawyer.
Promedia audits patient-facing pharma platforms across brands including GSK, J&J, and Amgen, and can share the methodology with in-house teams that prefer to run remediation themselves. If a disease awareness site under your responsibility has not been audited since the EAA came into force, that is the conversation worth having first.
One short email when we publish. No spam, no sales pitch. Unsubscribe whenever.
